IAS Statin Publication|
The International Atherosclerosis Society is very pleased to announce an exciting new and informative Newsletter for its membership: The IAS Statin Newsletter. The IAS will begin this month providing curated update on all publications involving statins as identified in PubMed.
For the Issues, click here
last updated: March 19, 2018
To access some of the content on athero.org
you must be a registered user and you must log on.
You can use the interface on the right side of this page to either log on or to register.
| From the IAS President's Desk |
The cholesteryl ester transfer protein (CETP) promotes the transfer of cholesteryl esters (CE) from high density lipoproteins (HDL) to apoB-containing lipoproteins, one of key steps of reverse cholesterol transport and its inhibition thus increases the concentration of HDL cholesterol while decreasing the cholesterol level in apoB-containing lipoproteins. The concept that CETP inhibition may prevent atherosclerosis because of these effects has been investigated, with varying results.
Cardiovascular clinical outcomes studies of the first three CETP inhibitors were terminated because of either increased mortality or futility despite marked increases in HDL-cholesterol, although in each case there were problems with either serious adverse effects unrelated to CETP (torcetrapib) or to trials that may have terminated too early (dalcetrapib and evacetrapib).
Severe FH Course “IDENTIFYING AND TREATING SEVERE FAMILIAL HYPERCHOLESTEROLEMIA” (Dubai, UAE, October 14-15, 2017)
The International Atherosclerosis Society (IAS), the Oman Society of Lipid and Atherosclerosis (OSLA), the Gulf Heart Association (GHA), and
the Emirates Cardiac Society (ECS), are happy to make available to our readers some important documents related to the Course on Identifying and Treating Severe Familial Hypercholesterolemia which
was held in Dubai, UAE on October 14-15, 2017. The Course was co-chaired by Profs. Raul Santos (President-Elect of IAS), Khalid Al-Rasadi (President, OSLA) and Wael Almahmeed (Board Member of GHA).
IAS SEVERE FH PANEL
IAS Consensus Statement “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”
The International Atherosclerosis Society (IAS) is proud to announce the publication on the definition of severe FH and the implications for clinical management in The Lancet Diabetes and Endocrinology. The IAS Severe FH Panel, made of 25 internationally renowned experts and chaired by Dr. Raul Santos, worked with the objective of characterizing the severe FH phenotype and made recommendations on how to stratify CVD risk and to whom to prescribe the novel lipid lowering treatments. These recommendations will contribute to improved daily clinical practice and better management of FH patients.
To download the full text, which is open access, please link to and register at http://www.thelancet.com/journals/landia/article/PIIS2213-8587(16)30041-9/fulltext (Published online May 27, 2016). For more information about The Lancet, please visit The Lancet Homepage at www.thelancet.com.
Other FH activities
NEW DATA ON FAMILIAL HYPERCHOLESTEROLEMIA IN BRAZIL
For the abstract and full article please click here
Improving management through genetic testing for Familial Hypercholesterolaemia (FH)
This e-learning has been developed for healthcare professionals with an interest in FH and genetic testing by a panel of world renowned experts in this area, Pr. Carrie and Pr. Bruckert from France, and Dr. Ballantyne and Dr. Eng in the USA and is approved by the International Atherosclerosis Society (IAS).
On completion of this e-learning you will have a better understanding of:
You can view the e-learning at http://www.cor2ed.com
- Key aspects of genetic testing in Familial Hypercholesterolaemia (FH)
- How and why to use genetic testing
- How to interpret results
- How to use cascade screening to identify related individuals at risk
NEWS FROM THE LIPID CLINICS in IRAQ
The success story deriving from the educational activities of the IAS and OSLA in the MENA Region continues. Thanks to the efforts of Dr. Mutaz Al-Sabah and his Iraqi colleagues at the moment 8 Lipid clinics have been established throughout the country:
We would love to hear from our member societies about other such exciting and important successes in the field throughout the world and look forward to hearing from you.
- Al-Diwaniya city
Al-Diwaniya teaching hospital
- Al-Sulaimaniya city
Shorsh military teaching hospital
- Al-Samawa city
Al-Samawa teaching hospital
- Salahaldeen city
Balad teaching hospital
- Al-Ramadi city
Al-Ramadi teaching hospital
- Al-Fallujah city
Al-Fallujah teaching hospital
- Erbil city
Rizgary teaching hospital
- Kirkuk city
Kirkuk lipid clinic
The SAFEHEART Registry
Risk factors for atherosclerotic cardiovascular disease (ASCVD) are variable among patients with Familial Hypercholesterolaemia (FH). SAFEHEART is a multicentre, nationwide, long-term prospective contemporary cohort study of a molecularly defined FH population with or without previous ASCVD. A robust risk prediction equation (SAFEHEART-RE) has been developed using this unique cohort that shows that the risk of incident ASCVD may be estimated in FH patients using clinical and laboratory parameters including age, gender, history of ASCVD, blood pressure, body mass index, smoking, and plasma LDL-C and lipoprotein (a) levels. The Harrell's C index for this model was 0.85.
You can view it here
This information will allow more accurate ASCVD risk prediction in FH and will potentially increase the efficiency of care and use of newer lipid lowering therapies. The SAFEHEART-RE is an accurate tool to implement these predictors in daily clinical practice.
| Antonio M. Gotto, Jr. Prize in Atherosclerosis Research - Nomination Deadline: February 2, 2018 |
The aim of the Gotto Prize is to encourage basic, clinical, and translational research in areas relating to the causes, prevention, and treatment of cardiovascular disease globally.
The award recipient will have provided and continues to provide outstanding scientific, medical, or organizational advancement in our ability to understand the causes and to reduce the development of atherosclerosis.
For more information click here.
| IAS - OSLA Collaboration in the MENA Region |
The International Atherosclerosis Society (IAS) and the Oman Society of Lipid and Atherosclerosis (OSLA) have recently organized the 4th IAS – OSLA Course on Lipid Metabolism and Cardiovascular Risk
which was held in Muscat, Oman (February 16-19, 2018).
Cochairs of the Course were Profs. Yuji Matsuzawa and Philip Barter of the International Atherosclerosis Society and Dr. Khalid Al-Rasadi of the Oman Society of Lipid and Atherosclerosis.
To view all highlights, please click here
| Meeting and Educational Activity Highlights |
The IAS wishes to thank all the supporters which have generously offered grants to the IAS for the development of its many activities and in support of its mission:|
Aegerion Pharmaceuticals, Amgen, Inc., Amgen (Europe) GmbH, Amryt, Daiichi Sankyo Co., Ltd., Fondazione Giovanni Lorenzini, OSLA - Oman Society of Lipids and Atherosclerosis, Ono Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd.,Pfizer, Sanofi and Regeneron, and Weill Cornell Medical College
This site is optimised for a min. 1024 x 768 pixels resolution
The International Atherosclerosis Society (IAS), incorporated in 1979, promotes, at an international level, the advancement of science, research and teaching in the field of atherosclerosis and related diseases.
|IAS Newsletter Editors & Website Editorial Board|
Scott M. Grundy, MD, PhD
Dallas, TX, USA
Houston, TX, USA
Commentary & Newsletter Editor
(Dallas, TX, USA)